[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2004073622A3 - Novel therapeutic method and compositions for topical administration - Google Patents

Novel therapeutic method and compositions for topical administration Download PDF

Info

Publication number
WO2004073622A3
WO2004073622A3 PCT/US2004/004329 US2004004329W WO2004073622A3 WO 2004073622 A3 WO2004073622 A3 WO 2004073622A3 US 2004004329 W US2004004329 W US 2004004329W WO 2004073622 A3 WO2004073622 A3 WO 2004073622A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
topical administration
therapeutic method
novel therapeutic
skin
Prior art date
Application number
PCT/US2004/004329
Other languages
French (fr)
Other versions
WO2004073622A2 (en
Inventor
Adrian Francis Davis
Lionel Trottet
Original Assignee
Smithkline Beecham Corp
Adrian Francis Davis
Lionel Trottet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Adrian Francis Davis, Lionel Trottet filed Critical Smithkline Beecham Corp
Priority to US10/545,773 priority Critical patent/US20060159648A1/en
Priority to EP04711167A priority patent/EP1594959A4/en
Priority to JP2006503567A priority patent/JP2006517973A/en
Publication of WO2004073622A2 publication Critical patent/WO2004073622A2/en
Publication of WO2004073622A3 publication Critical patent/WO2004073622A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

There is provided a method for treating a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands and skin cancer which comprises administering topically to the skin of a patient in need of treatment a pharmaceutical composition containing a drug substance which is a PPAR gamma agonist. There are also provided pharmaceutical compositions and uses thereof.
PCT/US2004/004329 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration WO2004073622A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/545,773 US20060159648A1 (en) 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration
EP04711167A EP1594959A4 (en) 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration
JP2006503567A JP2006517973A (en) 2003-02-17 2004-02-13 Novel therapeutic method and composition for topical administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0303609.2A GB0303609D0 (en) 2003-02-17 2003-02-17 Novel therapeutic method and compositions
GB0303609.2 2003-02-17

Publications (2)

Publication Number Publication Date
WO2004073622A2 WO2004073622A2 (en) 2004-09-02
WO2004073622A3 true WO2004073622A3 (en) 2005-01-20

Family

ID=9953158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/004329 WO2004073622A2 (en) 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration

Country Status (4)

Country Link
EP (1) EP1594959A4 (en)
JP (1) JP2006517973A (en)
GB (1) GB0303609D0 (en)
WO (1) WO2004073622A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
ITRM20050390A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
FR2894477A1 (en) * 2005-12-13 2007-06-15 Galderma Res & Dev USE OF NAVEGLITAZAR FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DERMATOLOGICAL DISEASES
IE20070129A1 (en) * 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
UA107562C2 (en) 2008-12-05 2015-01-26 METHOD OF TREATMENT OF PSORIASIS
US8754127B2 (en) 2009-02-16 2014-06-17 Nogra Pharma Limited Alkylamido compounds and uses thereof
EP2515830A4 (en) * 2009-12-21 2014-06-04 B C Unlimited Liability Company Compositions and methods for increasing cellular fat and bleaching skin
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
WO2013117744A2 (en) 2012-02-09 2013-08-15 Nogra Pharma Limited Methods of treating fibrosis
WO2013156413A1 (en) 2012-04-18 2013-10-24 Nogra Pharma Limited Methods of treating lactose intolerance
WO2014152843A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EP3094328B1 (en) 2014-01-15 2020-08-19 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
WO2018156552A1 (en) 2017-02-22 2018-08-30 Sugarman Jeffrey L Glitazones for topical application
BR112021015609A2 (en) 2019-02-08 2021-10-05 Nogra Pharma Limited MANUFACTURING PROCESS OF 3-(4?-AMINOPHENYL)-2-METHOXYPROPIONIC ACID, AND ANALOGS AND INTERMEDIARIES THEREOF
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166724A1 (en) * 2001-12-07 2003-09-04 Hangeland Jon J. Phenyl naphthol ligands for thyroid hormone receptor
US6747048B2 (en) * 2002-05-08 2004-06-08 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
AU2002303156A1 (en) * 2001-03-23 2002-10-08 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for ppar

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166724A1 (en) * 2001-12-07 2003-09-04 Hangeland Jon J. Phenyl naphthol ligands for thyroid hormone receptor
US6747048B2 (en) * 2002-05-08 2004-06-08 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANGELI V. ET AL: "Peroxisome Proliferator-Activated Receptor Inhibits the Migration of Dendritic Cells: Consequences for the Immune Response", JOURNAL OF IMMUNOLOGY, vol. 170, 2003, pages 5295 - 5301, XP002903615 *
See also references of EP1594959A4 *

Also Published As

Publication number Publication date
EP1594959A2 (en) 2005-11-16
GB0303609D0 (en) 2003-03-19
EP1594959A4 (en) 2006-05-03
JP2006517973A (en) 2006-08-03
WO2004073622A2 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
WO2004073622A3 (en) Novel therapeutic method and compositions for topical administration
US8580317B2 (en) Compositions and methods for treating acne
Song et al. Photodynamic therapy using chlorophyll-a in the treatment of acne vulgaris: a randomized, single-blind, split-face study
CA2549550A1 (en) Botulinum toxin therapy for skin disorders
WO2001005400A1 (en) Nitroimidazole external preparations for dermatosis
WO2006026469A3 (en) Pharmaceutical formulations of potassium atp channel openers and uses thereof
WO2004037184A3 (en) Methods for the treatment of skin disorders
WO2004084839A3 (en) Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
IL154888A (en) Non-aqueous pharmaceutical gel composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid and its use in the manufacture of a medicament for treatment of psoriasis
Paquette et al. Short-contact topical tretinoin therapy to stimulate granulation tissue in chronic wounds
EP1362581A3 (en) Combination antiperspirant and antimicrobial compositions
JP6298819B2 (en) Companion beauty composition
Sanclemente et al. A prospective split‐face double‐blind randomized placebo‐controlled trial to assess the efficacy of methyl aminolevulinate+ red‐light in patients with facial photodamage
MX2009007723A (en) Exenatide and dalargin-based medicinal preparation for treating pancreatic diabetes.
BRPI0510760A (en) method for administering to a patient a composition, topical composition, and patch
WO2004071397A3 (en) Combination therapy of zd6474 with 5-fu or/and cpt-11
US20190151394A1 (en) Prebiotic Acne Treatment
CN110339084A (en) A kind of formula and preparation method thereof of the antibacterial essence of polypeptide compound acne-removing
US11045503B2 (en) Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, chamomile and propolis
WO2008050157A2 (en) Ozonated oil formulations
Fabi et al. Treatment of acne in the aesthetic patient: A round table update
MX2010009578A (en) Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin d compound.
BRPI0508982A (en) use of azd2171 or a pharmaceutically acceptable salt thereof excluding an azd2171 maleate salt, pharmaceutical composition, kit, method for treating a cancer in a warm-blooded animal such as a human, and use of azd2171 maleate salt azd2171 and 5 - fu and cpt - 11
CN112843146A (en) New use of Chinese patent medicine sanhuang ointment
KR20220046542A (en) Methods and compositions for micro-filling skin with hyaluronic acid using microchannel technology

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004711167

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006503567

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2006159648

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10545773

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004711167

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10545773

Country of ref document: US